Nektar Therapeutics

$18.98 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of high unmet medical need. The Company's research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. Its programs include Immuno-oncology (I-O), Immunology, and Oncology-ONZEALD. It is developing medicines designed to directly or indirectly modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells.

Stock Analysis

last close $18.98
1-mo return -0.8%
3-mo return -17%
avg daily vol. 945.25T
52-week high 26.75
52-week low 15.4
market cap. $3.5B
forward pe -
annual div. -
roe -37.4%
ltg forecast -
dividend yield -
annual rev. $126M
inst own. 96.9%
baraka

Subscribe now for daily local and international financial news

Subscribe